SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-Tempest Provides Asco Kol Feedback On Tpst-1120 Clinical Results And Updated Financial Guidance

reuters.com · 06/09/2022 08:02
BRIEF-Tempest Provides Asco Kol Feedback On Tpst-1120 Clinical Results And Updated Financial Guidance

- Tempest Therapeutics Inc TPST:

  • TEMPEST PROVIDES ASCO KOL FEEDBACK ON TPST-1120 CLINICAL RESULTS AND UPDATED FINANCIAL GUIDANCE

  • TEMPEST THERAPEUTICS - RECIST RESPONSES SEEN WITH TPST-1120 COMBINED WITH ANTI-PD1 THERAPY IN PATIENTS WHO PREVIOUSLY PROGRESSED ON ANTI-PD1/PDL1 THERAPY

  • TEMPEST THERAPEUTICS INC - POTENTIAL BIOMARKER FOR PATIENT RESPONSIVENESS TO TPST-1120 IDENTIFIED AND WILL BE FURTHER EXPLORED

  • TEMPEST THERAPEUTICS INC - TPST-1120 DEMONSTRATED ABILITY TO REPROGRAM TME IN A TUMOR TYPE REFRACTORY TO ANTI-PD1 WITH LOW TUMOR MUTATION BURDEN

  • TEMPEST THERAPEUTICS INC - TPST-1120 DEMONSTRATED MONOTHERAPY CLINICAL BENEFIT IN PATIENTS WITH LATE-LINE ADVANCED, POOR-PROGNOSIS CANCERS

  • TEMPEST THERAPEUTICS INC - TPST-1120 WAS WELL TOLERATED AS BOTH A MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB

  • TEMPEST THERAPEUTICS INC - CASH AND CASH EQUIVALENTS ARE CURRENTLY EXPECTED TO BE SUFFICIENT TO FUND ITS CURRENT OPERATING PLANS INTO Q1 OF 2024

Source text for Eikon: ID:nGNX9kwKGt

Further company coverage: TPST


((reuters.briefs@thomsonreuters.com;))